AI Engines For more Details: Perplexity Kagi Labs You
Appetite Suppression: Amfepramone hydrochloride works by stimulating the release of norepinephrine in the brain, which leads to reduced appetite and increased feelings of fullness. It is typically used as a short-term adjunctive treatment for obesity in combination with diet and exercise.
Weight Loss: Amfepramone hydrochloride can help individuals achieve modest weight loss when used as part of a comprehensive weight management program. However, its long-term effectiveness for sustained weight loss is limited, and weight regain often occurs after discontinuation of treatment.
Central Nervous System Effects: Amfepramone hydrochloride may cause central nervous system (CNS) side effects, including nervousness, insomnia, restlessness, anxiety, and agitation. These effects are typically mild and transient but may be more pronounced in sensitive individuals or at higher doses.
Cardiovascular Effects: Amfepramone hydrochloride can increase heart rate and blood pressure, which may pose risks for individuals with pre-existing cardiovascular conditions or hypertension. Patients with cardiovascular risk factors should use amfepramone hydrochloride with caution and under the guidance of a healthcare professional.
Tolerance and Dependence: Like other appetite suppressants, amfepramone hydrochloride may lead to tolerance and dependence with long-term use. Patients may experience diminished effectiveness over time or develop withdrawal symptoms when discontinuing the medication abruptly.
Contraindications: Amfepramone hydrochloride is contraindicated in individuals with a history of cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, or a known hypersensitivity to sympathomimetic drugs. It should not be used in combination with other weight loss medications or monoamine oxidase inhibitors (MAOIs) due to the risk of serious adverse effects.
Psychiatric Effects: Amfepramone hydrochloride may exacerbate psychiatric conditions such as depression, bipolar disorder, or anxiety disorders. Patients with a history of psychiatric disorders should use amfepramone hydrochloride with caution and under close supervision.
Pregnancy and Breastfeeding: The safety of amfepramone hydrochloride use during pregnancy or breastfeeding has not been well established. It is generally recommended to avoid using appetite suppressants during pregnancy or breastfeeding due to potential risks to the fetus or infant.
Drug Interactions: Amfepramone hydrochloride may interact with other medications, including antidepressants, antipsychotics, monoamine oxidase inhibitors (MAOIs), and other sympathomimetic drugs. Concomitant use of these medications may increase the risk of serotonin syndrome or hypertensive crisis and should be avoided.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.1 | -0.1 | |
| ADHD | 1 | 0.1 | 9 |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | 0.4 | |
| Allergic Rhinitis (Hay Fever) | 0.1 | 0.6 | -5 |
| Allergies | 0.7 | 0.4 | 0.75 |
| Allergy to milk products | 0.1 | 0.1 | 0 |
| Alopecia (Hair Loss) | 0.1 | 0.1 | |
| Alzheimer's disease | 0.3 | 1.1 | -2.67 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.5 | 0.1 | 4 |
| Ankylosing spondylitis | 0.3 | 0.1 | 2 |
| Anorexia Nervosa | 0.3 | -0.3 | |
| Antiphospholipid syndrome (APS) | 0 | 0 | |
| Asthma | 0.2 | 0.5 | -1.5 |
| Atherosclerosis | 0.1 | 0.6 | -5 |
| Atrial fibrillation | 0.3 | 0.2 | 0.5 |
| Autism | 1.3 | 1.2 | 0.08 |
| Barrett esophagus cancer | 0 | 0 | 0 |
| Bipolar Disorder | 0.1 | 0.4 | -3 |
| Brain Trauma | 0.1 | 0.3 | -2 |
| Cancer (General) | 0.2 | 0.6 | -2 |
| Carcinoma | 0.5 | 0.4 | 0.25 |
| Celiac Disease | 0.3 | 0.7 | -1.33 |
| Cerebral Palsy | 0.2 | 0.3 | -0.5 |
| Chronic Fatigue Syndrome | 0.4 | 0.8 | -1 |
| Chronic Kidney Disease | 0.1 | 0.3 | -2 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.1 | 0.3 | -2 |
| Chronic Urticaria (Hives) | 0.1 | 0.1 | 0 |
| Coagulation / Micro clot triggering bacteria | 0 | 0.3 | 0 |
| Colorectal Cancer | 0.7 | 0.1 | 6 |
| Constipation | 0.1 | 0.3 | -2 |
| Coronary artery disease | 0 | 0 | |
| COVID-19 | 1.3 | 1.7 | -0.31 |
| Crohn's Disease | 0.8 | 0.7 | 0.14 |
| cystic fibrosis | 0.5 | -0.5 | |
| deep vein thrombosis | 0.3 | -0.3 | |
| Depression | 1.4 | 0.8 | 0.75 |
| Dermatomyositis | 0 | 0.1 | 0 |
| Eczema | 0 | 0.2 | 0 |
| Endometriosis | 0.3 | 0.2 | 0.5 |
| Eosinophilic Esophagitis | 0 | 0 | |
| Epilepsy | 0.3 | 0.3 | 0 |
| Fibromyalgia | 0.4 | 0.2 | 1 |
| Functional constipation / chronic idiopathic constipation | 0.4 | 0.5 | -0.25 |
| gallstone disease (gsd) | 0.1 | 0.4 | -3 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0 | 0 | 0 |
| Generalized anxiety disorder | 0 | 0.4 | 0 |
| Glioblastoma | 0 | 0 | |
| Graves' disease | 0.2 | 0.4 | -1 |
| Halitosis | 0.1 | 0 | 0 |
| Hashimoto's thyroiditis | 0.6 | 0.2 | 2 |
| Hidradenitis Suppurativa | 0 | 0 | 0 |
| High Histamine/low DAO | 0.3 | 0.1 | 2 |
| hypercholesterolemia (High Cholesterol) | 0.2 | 0.1 | 1 |
| hyperglycemia | 0 | 0.3 | 0 |
| Hyperlipidemia (High Blood Fats) | 0.2 | 0.2 | |
| hypersomnia | 0 | 0 | |
| hypertension (High Blood Pressure | 0.2 | 1.7 | -7.5 |
| Hypothyroidism | 0.2 | -0.2 | |
| Hypoxia | 0.1 | 0.1 | |
| IgA nephropathy (IgAN) | 0.1 | -0.1 | |
| Inflammatory Bowel Disease | 0.3 | 0.8 | -1.67 |
| Insomnia | 0.1 | 0.3 | -2 |
| Intracranial aneurysms | 0.1 | 0.1 | |
| Irritable Bowel Syndrome | 0.6 | 0.6 | 0 |
| Liver Cirrhosis | 0.8 | 0.6 | 0.33 |
| Long COVID | 0.6 | 1.2 | -1 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.1 | 0.2 | -1 |
| Mast Cell Issues / mastitis | 0 | 0.1 | 0 |
| ME/CFS with IBS | 0 | 0.3 | 0 |
| ME/CFS without IBS | 0.2 | 0.4 | -1 |
| Menopause | 0.5 | 0.5 | |
| Metabolic Syndrome | 0.9 | 2 | -1.22 |
| Mood Disorders | 1.6 | 0.9 | 0.78 |
| multiple chemical sensitivity [MCS] | 0.2 | 0 | 0 |
| Multiple Sclerosis | 0.8 | 0.4 | 1 |
| Multiple system atrophy (MSA) | 0.7 | 0.1 | 6 |
| neuropathic pain | 0.7 | -0.7 | |
| Neuropathy (all types) | 0.1 | 0.1 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.2 | 0.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.1 | 0.9 | -8 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.2 | 0.5 |
| Obesity | 1.7 | 0.6 | 1.83 |
| obsessive-compulsive disorder | 0.4 | 0.5 | -0.25 |
| Osteoarthritis | 0.1 | 0.1 | |
| Osteoporosis | 0.2 | 0.2 | 0 |
| pancreatic cancer | 0.2 | 0.2 | |
| Parkinson's Disease | 0.5 | 0.5 | 0 |
| Polycystic ovary syndrome | 0.1 | 0.6 | -5 |
| Postural orthostatic tachycardia syndrome | 0.1 | -0.1 | |
| Premenstrual dysphoric disorder | 0.1 | 0.1 | |
| primary biliary cholangitis | 0.1 | 0.1 | |
| Psoriasis | 0.4 | 0.4 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.7 | 0.7 | 0 |
| Rosacea | 0.1 | 0.3 | -2 |
| Schizophrenia | 1 | 0.4 | 1.5 |
| Sjögren syndrome | 0.3 | 0.6 | -1 |
| Sleep Apnea | 0.1 | 0.4 | -3 |
| Slow gastric motility / Gastroparesis | 0.1 | 0.1 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0 | 0.2 | 0 |
| Stress / posttraumatic stress disorder | 0.6 | 0.7 | -0.17 |
| Systemic Lupus Erythematosus | 0.3 | 0.6 | -1 |
| Tic Disorder | 0.2 | 0.2 | 0 |
| Tourette syndrome | 0 | 0.1 | 0 |
| Type 1 Diabetes | 0.1 | 0.6 | -5 |
| Type 2 Diabetes | 0.9 | 0.8 | 0.13 |
| Ulcerative colitis | 0.3 | 0.7 | -1.33 |
| Unhealthy Ageing | 0.5 | 0.6 | -0.2 |
| Vitiligo | 0.1 | 0.2 | -1 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [98.80.143 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [98.80.143 ]
